MC
BIB icon

Moors & Cabot’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

Moors & Cabot’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-4,000
Closed -$207K – 673
2019
Q2 		$207K Buy
+4,000
New +$199K 0.03% 504

Other funds holding BIB

CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
SBIA
Sheaff Brock Investment Advisors Indianapolis, Indiana $1.09B AUM 14.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
CAL
Capital Analysts LLC Fort Washington, Pennsylvania $3.81B AUM 15.52% 1-Year Est. Return

Moors & Cabot's BIB Position: Q3 2019 in Review

Moors & Cabot sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q3 2019, closing a stake of 4,000 shares — an estimated $207K sold.

Moors & Cabot first reported a position in BIB in Q2 2019 and held it in 1 quarter. The position peaked at $207K in Q2 2019. 25 funds tracked by Wall St. Rank hold BIB as of Q3 2019.

  • Moors & Cabot reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q3 2019 after selling out during the quarter.
  • Moors & Cabot sold 4,000 ProShares Ultra NASDAQ Biotechnology shares in Q3 2019, an estimated $207K.
  • Moors & Cabot first reported a position in ProShares Ultra NASDAQ Biotechnology in Q2 2019 and held it in 1 quarter.
  • Moors & Cabot's ProShares Ultra NASDAQ Biotechnology position peaked at $207K in Q2 2019.
  • 25 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q3 2019.

Based on Moors & Cabot's 13F filing for Q3 2019, filed 22 Oct 2019.